Advanced search
Publication Cover
Leukemia & Lymphoma Volume 61, 2020 - Issue 6
Submit an article Journal homepage
3,780
Views
15
CrossRef citations to date
0
Altmetric
Original Articles

Health-related quality of life results from the IFM 2009 trial: treatment with lenalidomide, bortezomib, and dexamethasone in transplant-eligible patients with newly diagnosed multiple myeloma

Murielle RousselInstitut Universitaire du Cancer de Toulouse-Oncopole and University Hospital, Toulouse, France; Correspondence[email protected]
ORCID Iconhttp://orcid.org/0000-0002-4045-9428View further author information
ORCID Icon,
Benjamin HebraudInstitut Universitaire du Cancer de Toulouse-Oncopole and University Hospital, Toulouse, France; View further author information
,
Cyrille HulinCHU, Bordeaux, France; View further author information
,
Aurore PerrotCHU de Nancy, University of Lorraine, Nancy, France; View further author information
,
Denis CaillotHôpital du Bocage, CHU de Dijon, Dijon, France; View further author information
,
Anne-Marie StoppaHematologie clinique, Institut Paoli-Calmettes, Marseille, France; View further author information
,
Margaret MacroHôpital Côte de Nacre, CHU de Caen, Caen, France; View further author information
,
Martine EscoffreHematologie clinique, Institut Paoli-Calmettes, Marseille, France; View further author information
,
Bertrand ArnulfHôpital Saint-Louis, AP-HP, Paris, France; View further author information
,
Karim BelhadjCHU Henri Mondor, Créteil, France; View further author information
,
Lionel KarlinHématologie clinique, CHU de Lyon HCL – GH Sud, Pierre-Bénite, France; View further author information
,
Laurent GarderetHôpital Pitié Salpétriere Saint-Antoine, AP-HP, Paris, France; View further author information
,
Thierry FaconHôpital Claude Huriez, CHRU de Lille, Lille, France; View further author information
,
Shien GuoEvidera, Waltham, MA, USA; View further author information
,
Josh WengEvidera, Waltham, MA, USA; ORCID Iconhttp://orcid.org/0000-0002-4951-9298View further author information
ORCID Icon,
Sujith DhanasiriCelgene International, A Bristol-Myers Squibb Company, Boudry, Switzerland; View further author information
,
Xavier LeleuPoitiers University Hospital, Poitiers, France; View further author information
,
Philippe MoreauNantes University Hospital, Nantes, FranceView further author information
&
Michel AttalInstitut Universitaire du Cancer de Toulouse-Oncopole and University Hospital, Toulouse, France; View further author information
 show all
Pages 1323-1333 | Received 30 Sep 2019, Accepted 10 Jan 2020, Published online: 22 Feb 2020

Citations (15)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (2)

Meghana Kesireddy & Sarah A. Holstein. (2022) The era of lenalidomide maintenance therapy in multiple myeloma: settings for achieving best outcomes. Expert Review of Clinical Pharmacology 15:1, pages 19-31.
Read now
Mir M. Asrar, Deepesh P. Lad, Dipika Bansal, Shankar Prinja, Alka Khadwal, Gaurav Prakash, Arihant Jain, Aditya Jandial & Pankaj Malhotra. (2021) Health-related quality of life in transplant eligible multiple myeloma patients with or without early ASCT in the real-world setting. Leukemia & Lymphoma 62:13, pages 3271-3277.
Read now

Articles from other publishers (13)

Clifton Mo, Monique Hartley-Brown, Shonali Midha & Paul Richardson. (2023) Upfront or Deferred Autologous Stem Cell Transplantation for Newly Diagnosed Multiple Myeloma in the Era of Triplet and Quadruplet Induction and Minimal Residual Disease/Risk-Adapted Therapy. Cancers 15:24, pages 5709.
Crossref
Amelie Boquoi, Aristoteles Giagounidis, Hartmut Goldschmidt, Michael Heinsch, Mathias J. Rummel, Nicolaus Kröger, Elias K. Mai, Judith Strapatsas, Rainer Haas & Guido Kobbe. (2023) Health-Related Quality of Life in Multiple Myeloma Patients Treated with High- or Low-Dose Lenalidomide Maintenance Therapy after Autologous Stem Cell Transplantation—Results from the LenaMain Trial (NCT00891384). Cancers 15:21, pages 5157.
Crossref
Paul G. Richardson, Brian G. Durie, Laura Rosiñol, Maria-Victoria Mateos, Angela Dispenzieri, Philippe Moreau, Shaji Kumar, Noopur Raje, Nikhil Munshi, Jacob P. Laubach, Peter O’Gorman, Elizabeth O’Donnell, Peter Voorhees, Thierry Facon, Joan Bladé, Sagar Lonial, Aurore Perrot & Kenneth C. Anderson. (2023) Clinical perspectives on the optimal use of lenalidomide plus bortezomib and dexamethasone for the treatment of newly diagnosed multiple myeloma. Haematologica 108:11, pages 2894-2912.
Crossref
Rajshekhar Chakraborty, Jean Yi, Lisa Rybicki, Jaime Preussler, Abhinav Deol, Alison Loren, Bipin Savani, Heather S.L. Jim, Jan Cerny, Jana Reynolds, Jennifer Whitten, John R. Wingard, Joseph P. McGuirk, Joseph Uberti, Nandita Khera, Patrick Stiff, Samantha M. Jaglowski, Shahrukh Hashmi, Shernan G. Holtan, Steven Devine, Theresa Hahn, Victoria L. Whalen, Wael Saber, William Wood, K. Scott Baker, Karen Syrjala & Navneet S. Majhail. (2023) Patient-Reported Outcomes in Long-Term Survivors of Autologous Hematopoietic Cell Transplantation in Multiple Myeloma. Transplantation and Cellular Therapy 29:6, pages 388.e1-388.e6.
Crossref
Anita D'Souza, Ruta Brazauskas, Edward A. Stadtmauer, Marcelo C. Pasquini, Parameswaran Hari, Asad Bashey, Natalie Callander, Steven Devine, Yvonne Efebera, Siddhartha Ganguly, Cristina Gasparetto, Nancy Geller, Mary M. Horowitz, John Koreth, Heather Landau, Claudio Brunstein, Philip McCarthy, Muzaffar H. Qazilbash, Sergio Giralt, Amrita Krishnan & Kathryn E. Flynn. (2022) Trajectories of quality of life recovery and symptom burden after autologous hematopoietic cell transplantation in multiple myeloma. American Journal of Hematology 98:1, pages 140-147.
Crossref
Ajay Major, Andrzej Jakubowiak & Benjamin Derman. (2022) Longitudinal Real-World Neuropathy and Patient-Reported Outcomes With Bortezomib and Lenalidomide in Newly Diagnosed Multiple Myeloma. Clinical Lymphoma Myeloma and Leukemia 22:11, pages e1000-e1008.
Crossref
Fabio Efficace, Francesco Cottone, Francesco Sparano, Giovanni Caocci, Marco Vignetti & Rajshekhar Chakraborty. (2022) Patient-Reported Outcomes in Randomized Controlled Trials of Patients with Multiple Myeloma: A Systematic Literature Review of Studies Published Between 2014 and 2021. Clinical Lymphoma Myeloma and Leukemia 22:7, pages 442-459.
Crossref
Krina K. Patel, Jatin J. Shah, Lei Feng, Hans C. Lee, Elisabet M. Manasanch, Jasper Olsem, Ashley Morphey, Xiao Jiao Huo, Sheeba K. Thomas, Qaiser Bashir, Muzaffar H. Qazilbash, Donna M. Weber & Robert Z. Orlowski. (2022) Safety and Efficacy of Combination Maintenance Therapy with Ixazomib and Lenalidomide in Patients with Posttransplant Myeloma. Clinical Cancer Research 28:7, pages 1277-1284.
Crossref
Yuan Yao, Wei-Wei Sui, Ai-Jun Liao, Wei Wang, Li-Juan Chen, Xiao-Xia Chu, Li Bao, Xi-Nan Cen, Rong Fu, Hui Liu, Chun-Yan Sun, Feng-Yan Jin, Hua Yan, Lu-Qun Wang, Cheng-Lu Yuan, Guang-Xun Gao, Da Gao, Jin-Qiao Zhang, Jian-Xia He, Jian-Da Hu, Liang-Ming Ma, Lu Zhang, Dao-Bin Zhou, De-Hui Zou & Jian Li. (2022) Comprehensive geriatric assessment in newly diagnosed older myeloma patients: a multicentre, prospective, non-interventional study. Age and Ageing 51:1.
Crossref
Richard LeBlanc, Debra J. Bergstrom, Julie Côté, Rami Kotb, Martha L. Louzada & Heather J. Sutherland. (2022) Management of Myeloma Manifestations and Complications: The Cornerstone of Supportive Care: Recommendation of the Canadian Myeloma Research Group (formerly Myeloma Canada Research Network) Consensus Guideline Consortium. Clinical Lymphoma Myeloma and Leukemia 22:1, pages e41-e56.
Crossref
Mohammed S. Ebraheem, Hsien Seow, Amaris K. Balitsky, Gregory R. Pond, Tanya M. Wildes, Branavan Sivapathasundaram, Jonathan Sussman & Hira Mian. (2021) Trajectory of Symptoms in Patients Undergoing Autologous Stem Cell Transplant for Multiple Myeloma: A Population-Based Cohort Study of Patient-Reported Outcomes. Clinical Lymphoma Myeloma and Leukemia 21:9, pages e714-e721.
Crossref
Murielle Roussel, Philippe Moreau, Benjamin Hebraud, Kamel Laribi, Arnaud Jaccard, Mamoun Dib, Borhane Slama, Véronique Dorvaux, Bruno Royer, Laurent Frenzel, Sonja Zweegman, Saskia K Klein, Annemiek Broijl, Kon-Siong Jie, Jianping Wang, Veronique Vanquickelberghe, Carla de Boer, Tobias Kampfenkel, Katharine S Gries, John Fastenau & Pieter Sonneveld. (2020) Bortezomib, thalidomide, and dexamethasone with or without daratumumab for transplantation-eligible patients with newly diagnosed multiple myeloma (CASSIOPEIA): health-related quality of life outcomes of a randomised, open-label, phase 3 trial. The Lancet Haematology 7:12, pages e874-e883.
Crossref
Titouan Cazaubiel, Olga Mulas, Lydia Montes, Anaïs Schavgoulidze, Hervé Avet-Loiseau, Jill Corre & Aurore Perrot. (2020) Risk and Response-Adapted Treatment in Multiple Myeloma. Cancers 12:12, pages 3497.
Crossref

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.